In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CardioDx gets $34.6mm through Series D venture round

Executive Summary

CardioDx Inc. (developing cardiovascular diagnostics) has brought in $34.6mm of a potential $44.5mm Series D venture round. GE Healthcare led the financing with a $5mm investment through its newly formed Healthymagination Fund. Fellow first-time backer DAG Ventures was joined by current shareholders Asset Management, Kleiner Perkins Caufield & Byers, Intel Capital, Mohr Davidow Ventures, Pappas Ventures, and TPG Ventures, as well as seven other undisclosed investors.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies